Collectively, our results indicate that combination treatment with CL7 and anti-PD-1 could be a novel therapeutic option for suppressing breast cancer growth and metastasis by reprogramming the TME through an increase in M1 TAMs and the activation of CD8+ T cells and NK cells. Here, CD8A is linked to breast carcinoma.